ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±·¿Ê«æᢡ¢ÁõÎÄÇÙ¡¢¡¢»Æ©¼¡²ã½þÈóÐÔ°òë×°©£¨MIBC£©Õ¼ËùÓаòë×Äò·ÉÏƤ°©±ÈÀýԼΪ25% £¬£¬£¬ÆäÔ¤ºó½Ï²î £¬£¬£¬»¼Õß5ÄêÉúÑÄÂÊȱ·¦50%¡£¡£½üÄêÀ´ £¬£¬£¬Ëæ×ÅÃâÒß¼ì²éµãÒÖÖƼÁµÄ·ºÆ𠣬£¬£¬MIBCµÄи¨ÖúÖÎÁÆÈ¡µÃÁËÏÔÖøÏ£Íû¡£¡£
¿ËÈÕ £¬£¬£¬ngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîÒ½ÔºÁÖÌì짽ÌÊںͻƽ¡½ÌÊÚÁìÏεĺ£ÄÚ¶àÖÐÐÄÁÙ´²Ñо¿£¨BGB-A317-2002£©Ì½ÌÖÁËÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÖйúMIBC»¼ÕßµÄÁÆЧ¡¢¡¢Çå¾²ÐÔ¼°Ç±ÔÚµÄÔ¤²âÐÔÉúÎï±ê¼ÇÎï¡£¡£ÕâÏîÑо¿ÎªÖйúMIBC»¼ÕßµÄÖÎÁÆÌṩÁËÖ÷ÒªµÄÑ֤ҽѧ֧³Ö £¬£¬£¬²¢ÓÚ2024Äê9ÔÂ10ÈÕ £¬£¬£¬ÔÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯¡¶Nature Cancer¡·ÉÏ £¬£¬£¬½ÒÏþÁËÌâΪ¡¶Neoadjuvant gemcitabine¨Ccisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial¡±¡·µÄÂÛÎÄ¡£¡£¸ÃÂÛÎĵÄͨѶ×÷ÕßΪÁÖÌì짡¢¡¢»Æ½¡½ÌÊÚ £¬£¬£¬ÀîïÇÎĸ±Ö÷ÈÎҽʦºÍÖÓÎÄÁúÖ÷ÖÎҽʦΪÅäºÏµÚÒ»×÷Õß¡£¡£
BGB-A317-2002Ñо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢¡¢¿ª·Å±êÇ©¡¢¡¢µ¥±ÛµÄIIÆÚÁÙ´²ÊÔÑé £¬£¬£¬Ö¼ÔÚÆÀ¹ÀÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÔÚÖйúMIBC»¼ÕßÖеÄÓÐÓÃÐÔ¡¢¡¢Çå¾²ÐÔ¼°Ô¤²âÉúÎï±ê¼ÇÎï¡£¡£Ñо¿ÓÉngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîҽԺǣͷ £¬£¬£¬Î÷°²½»Í¨´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº¡¢¡¢°²»ÕÒ½¿Æ´óѧµÚ¶þÒ½Ôº¡¢¡¢±±¾©´óѧÈËÃñÒ½ÔººÍɽ¶«Ê¡Á¢Ò½ÔºµÈ¶¥¼¶ÃÚÄòÍâ¿ÆÖÐÐÄÅäºÏ¼ÓÈë¡£¡£
Ñо¿µÄÖ÷ÒªÖÕµãΪ²¡ÀíÍêÈ«»º½âÂÊ£¨pCR£© £¬£¬£¬´ÎÒªÖÕµã°üÀ¨ÊÂÎñÎÞÏ£ÍûÉúÑÄ£¨EFS£©¡¢¡¢ÎÞ¸´±¬·¢ÑÄ£¨RFS£©¡¢¡¢×ÜÉúÑÄÂÊ£¨OS£©¼°Çå¾²ÐԵȡ£¡£ÔÚ57Àý½ÓÊܸùÖÎÐÔÊÖÊõµÄ»¼ÕßÖÐ £¬£¬£¬pCRÂÊ´ï50.9% £¬£¬£¬ÇкÏÔ¤ÉèµÄͳ¼ÆѧÖյ㠣¬£¬£¬ÌáÐѸÃÖÎÁÆ·½°¸¾ßÓÐÆð¾¢µÄÁÙ´²ÒâÒå¡£¡£×îеÄËæ·ÃÊý¾ÝÏÔʾ £¬£¬£¬1ÄêEFS¡¢¡¢OSºÍRFSÂÊ»®·ÖΪ89.3%¡¢¡¢91.2%ºÍ85.2%¡£¡£±ðµÄ £¬£¬£¬¸Ãи¨ÖúÖÎÁÆ·½°¸µÄÇå¾²ÐÔºÍÄÍÊÜÐÔÓÅÒì¡£¡£ÉúÎï±ê¼ÇÎïÑо¿ÏÔʾ £¬£¬£¬ÃâÒßÑ×Ö¢±íÐÍ×黼ÕßµÄpCRÂʸߴï80%¡£¡£
ÀúÊ·ÉϵÄи¨Öú»¯ÁÆ·½°¸ £¬£¬£¬pCRÂÊ£¨²¡ÀíÍêÈ«»º½âÂÊ£©Í¨³£Îª21%-30% £¬£¬£¬pDSÂÊ£¨²¡Àí½µÆÚÂÊ£©Í¨³£Ð¡ÓÚ50% £¬£¬£¬¶ø±¾Ñо¿µÄpCRºÍpDSÂʽÏÀúÊ·Êý¾Ý¾ùÌá¸ßÁË20%ÒÔÉÏ¡£¡£±ðµÄ £¬£¬£¬±¾Ñо¿ÖÐcT2»¼Õߣ¨ÁÙ´²Õï¶ÏΪT2ÆÚÖ×ÁöµÄ»¼Õߣ©µÄpCRÂʺÍpDSÂÊ»®·ÖµÖ´ï55.6%ºÍ86.1% £¬£¬£¬¸ßÓÚÒÔÍùµÄÑо¿Êý¾Ý¡£¡£Í¬Ê± £¬£¬£¬ÓëÆäËûÃâÒßÁªºÏ˳²¬»¯ÁƵÄÑо¿Ïà±È £¬£¬£¬±¾Ñо¿µÄpCRÂÊ£¨33%-49%£©Ò²ÓâÔ½ÁËÒÔÍùÑо¿µÄÉÏÏÞ¡£¡£
ÖµµÃ×¢ÖصÄÊÇ £¬£¬£¬±¾Ñо¿Ì½Ë÷ÁËÓëи¨ÖúÃâÒßÁªºÏÖÎÁÆÓ¦´ðÏà¹ØµÄDZÔÚÉúÎï±ê¼ÇÎï £¬£¬£¬È·¶¨ÁËÈýÖÖMIBC£¨¼¡²ã½þÈóÐÔ°òë×°©£©ÑÇÐÍ£º£º£ºS1£¨ÃâÒß»ÄÔ±íÐÍ£©¡¢¡¢S2£¨ÃâÒßÇãÔþ±íÐÍ£©ºÍS3£¨ÃâÒßÑ×Ö¢±íÐÍ£© £¬£¬£¬ÏÔʾÁËÔÚи¨ÖúÃâÒß»¯ÁÆÖÐÔ¤²â»ñÒ滼ÕßµÄDZÁ¦¡£¡£
±¾Ñо¿Äý¾ÛÁ˺£ÄÚ6¼Ò´óÐÍÃÚÄòÍâ¿ÆÖÐÐĵÄÁÙ´²ÂÄÀú £¬£¬£¬ÀúʱÎåÄê £¬£¬£¬×îÖÕ½ÒÏþÔÚ¡¶Nature Cancer¡·ÕâÒ»¹ú¼Ê¶¥¼¶ÆÚ¿¯ÉÏ¡£¡£ÔÚÁÆЧ·½Ãæ £¬£¬£¬¸Ã·½°¸ÔÚpCRºÍpDSÂÊÉÏ´¦ÓÚ¹ú¼ÊͬÀàÑо¿µÄÁìÏÈλÖᣡ£Ñо¿ÎªÖйúMIBC»¼Õßи¨ÖúÃâÒßÁªºÏ»¯ÁƵÄÁÙ´²Ó¦ÓÃÌṩÁËÖ÷ÒªµÄÖ¤¾Ý £¬£¬£¬¾ßÓм«´óµÄÁÙ´²Íƹã¼ÛÖµ¡£¡£
ÔÎÄÁ´½Ó£º£º£ºhttps://doi.org/10.1038/s43018-024-00822-0
µØµã:¹ãÖÝÊÐиÛÎ÷·135ºÅ Óʱà:510275
µç»°: 020-84112828
ngµç×ÓÓÎÏ·°æȨËùÓÐ COPYRIGHT?1999-2022 , SUN YAT-SEN UNIVERSITY